Verona Pharma meeting its primary objective in its dose ranging Phase IIa trial of RPL554 in asthma patients is extremely encouraging and follows the unequivocally positive results from all three parts of its Phase I/IIa trial in COPD during 2015. The compound continues to demonstrate an attractive profile with its combined bronchodilator and anti-inflammatory properties, representing a novel approach to the treatment of respiratory disease. We continue to look forward to top-line data from a Phase II trial evaluating the addition of RPL554 to standard reliever medications for COPD in Q2’16. We remain extremely upbeat and see significant upside potential.
